{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-041807","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.426601+00:00","generated_at":"2026-05-16T20:17:40.177860+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Grace Therapeutics reports Q2 loss of $0.9M; FDA accepts NDA for GTx-104 with PDUFA April 23, 2026","bullets":["Net loss $0.9M ($0.06 loss per share) vs $3.4M ($0.30 loss) in Q2 last year.","FDA accepted NDA for GTx-104 (nimodipine IV) for aSAH; PDUFA target date April 23, 2026.","U.S. patent issued for IV dosing regimen; IP protection extended to 2043.","Cash $16.9M at Sept 30, 2025; ~$20.0M at Oct 31, 2025 after $4.0M warrant exercises.","R&D expenses fell 80% to $0.6M due to completion of Phase 3 STRIVE-ON trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-041807","json":"https://secwatch.observer/filing/0001140361-25-041807.json","markdown":"https://secwatch.observer/filing/0001140361-25-041807.md","text":"https://secwatch.observer/filing/0001140361-25-041807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/0001140361-25-041807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:17:40.177860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}